Description: OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Home Page: onkuretherapeutics.com
6707 Winchester Circle
Boulder,
CO
80301
United States
Phone:
720 307 2892
Officers
| Name | Title |
|---|---|
| Dr. Nicholas A. Saccomano Ph.D. | President, CEO & Director |
| Mr. Jason A. Leverone CPA | Chief Financial Officer |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary |
| Prof. Xuedong Liu Ph.D. | Member of Scientific Advisory Board |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
| Dr. Duncan Walker Ph.D. | Chief Development Officer |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-10-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |